First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK),
immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.